News | Radiation Dose Management | August 14, 2018

Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence

Partnership will work to reduce variability and improve quality, safety and efficiency of care around radiation dose management

Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence

August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of artificial intelligence (AI) process and workflow solutions. The Imalogix Platform gives healthcare organizations the tools to understand and manage the process, quality and safety related to diagnostic imaging and interventional procedures, and meet evolving regulatory standards surrounding radiation dose management with ease.

The commercial partnership combines Guerbet's capabilities in diagnostic and interventional imaging with the cloud-based human and machine-intelligence capabilities of Imalogix to proactively identify areas that impact care delivery. The goal is to reduce variability and improve the quality, safety and efficiency of care around radiation dose management.

The Imalogix self-learning neural network enables organizations to understand and benchmark in real-time best practices from the mass learnings across a network of providers to drive continuous improvement. Deep learning recommendations highlight where and how changes can be made to enable organizations to proactively change behavior down to the scanner, protocol and operator level. Insights into procedure length, utilization and workflow help organizations understand how to become more efficient and optimize patient flow.

For more information: www.guerbet.com, www.imalogix.com

Related Content

Rensselaer, First-Imaging, and GE Global researchers develop a deep neural network to perform nearly as well as more complex dual-energy CT imaging technology
News | Computed Tomography (CT) | October 20, 2020
October 20, 2020 — Bioimaging technologies are the eyes that allow doctors to see inside the body in order to diagnos
Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.
News | Artificial Intelligence | October 20, 2020
October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using...
The use of CT and X-ray in the assessment and treatment plan for President Trump underscores the critical role that medical imaging must play in the fight against COVID-19

A COVID-19 chest CT heat map from RADlogics

News | Artificial Intelligence | October 13, 2020
October 13, 2020 — Given recent high-profile cases of...
Visual technology company, EIizo, has showcased its work with the world-renowned National Gallery, after monitors from its ColorEdge product line were used to document and investigate part of its extensive collection.
News | Flat Panel Displays | October 08, 2020
November 8, 2020 — Visual technology company, EIizo, has showcased its work with the world-renowned...